Inflazyme Pharmaceuticals Ltd.
NEX BOARD : IZP.H

Inflazyme Pharmaceuticals Ltd.

April 29, 2008 22:00 ET

Inflazyme Appoints Alan Savage to Board of Directors

VANCOUVER, BRITISH COLUMBIA--(Marketwire - April 29, 2008) - Inflazyme Pharmaceuticals Ltd. (Inflazyme) (NEX:IZP.H) announced today that Alan Savage has been appointed to the Inflazyme Board of Directors. "We welcome Alan to join our Board of Directors as we proceed to review the alternative plans for Inflazyme in the upcoming weeks," said Jeremy Curnock Cook, Chairman of Inflazyme.

Alan Savage is currently President and CEO of Southern Gold Resources Ltd., a privately held oil royalty and equity investment company that has been in operation since 1981. He was Director and CEO of Doublestar Resources Ltd. from 1996 to 2007. Mr. Savage is presently a Director of several Canadian public companies including Canadian Zinc Corporation and Selkirk Metals Corporation.

About Inflazyme

Inflazyme Pharmaceuticals is a biopharmaceutical company that developed products in respiratory and inflammatory diseases. Further information on the Company may be obtained from its website at www.inflazyme.com or on SEDAR at www.sedar.com.

This news release contains certain "forward-looking statements" and "forward-looking information" which may include but is not limited to statements in respect of our future financial position or operations. Words like "believe", "intend", "may", "expect", "anticipate", "plan", "should" and other similar expressions are forward-looking statements that involve a number of risks and uncertainties. By their nature, forward-looking statements involve numerous factors, assumptions and estimates, some but not all of the factors that could cause actual results to differ materially from those projected in our forward-looking statements include among others: risks associated with the completion of clinical trials and obtaining regulatory approval to market our products, market acceptance of our technologies and products; our ability to obtain financing; our financial and technical resources relative to those of our competitors; our ability to enforce our intellectual property rights and protect our proprietary technologies; the ability to obtain and develop partnership opportunities; and other risk factors identified from time to time in the Company's regulatory filings. For a further description of the principal risks affecting the Company, see our regulatory filings. These factors should be considered carefully and readers are cautioned not to place undue reliance on such forward-looking statements. The Company disclaims any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements.

Contact Information

  • Inflazyme Pharmaceuticals Ltd.
    Julie Rezler
    Sr. Director, Corporate Development
    Toll Free: 1-800-315-3660 or (604) 279-8511
    (604) 279-8711 (FAX)
    Email: ir@inflazyme.com
    Website: www.inflazyme.com